Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study

Published:2017-04-12 Issue:8 Volume:56 Page:1293-1301
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:

Author:

Kubo Satoshi,Yamaoka Kunihiro,Amano Koichi,Nagano Shuji,Tohma Shigeto,Suematsu Eiichi,Nagasawa Hayato,Iwata Kanako,Tanaka Yoshiya

Funder

Ministry of Health

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/56/8/1293/18801161/kex068.pdf

Reference38 articles.

1. Treating rheumatoid arthritis to target: recommendations of an international task force;Ann Rheum Dis,2010

2. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease;Immunity,2012

3. A quantitative analysis of kinase inhibitor selectivity;Nat Biotechnol,2008

4. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550);J Immunol,2011

5. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis;N Engl J Med,2012

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study;RMD Open;2023-04

2. Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial;Chinese Medical Journal;2023-02-05

3. 2) Development and Future Challenges in Treatment of Rheumatic Diseases;Nihon Naika Gakkai Zasshi;2022-09-10

4. Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: A prospective cohort study;PLOS ONE;2022-06-23

5. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology;Rheumatology Science and Practice;2022-05-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3